Literature DB >> 26068520

Mechanism-based inactivation of CYP2C9 by linderane.

Hui Wang1, Kai Wang1, Xu Mao1, Qingqing Zhang1, Tong Yao1, Ying Peng1, Jiang Zheng2,3.   

Abstract

1. Linderane (LDR), a furan-containing sesquiterpenoid, is found in Lindera aggregata (Sims) Kosterm, a common traditional Chinese herbal medicine. We thoroughly studied the irreversible inhibitory effect of LDR on cytochrome P450 2C9 (CYP2C9). 2. LDR caused a time- and concentration-dependent inactivation of CYP2C9. In addition, the inactivation of CYP2C9 by LDR was NADPH-dependent and irreversible. More than 50% of CYP2C9 activity was lost after its incubation with LDR at the concentration of 10 μM for 15 min at 30 °C. The maximal rate constant for inactivation (kinact) was found to be 0.0419 min(-1), and the concentration required for half-maximal inactivation (KI) was 1.26 μM, respectively. Glutathione (GSH), catalase, and superoxide dismutase (SOD) failed to protect CYP2C9 against inactivation by LDR. Diclofenac, a substrate of CYP2C9, prevented the enzyme from inactivation produced by LDR. The estimated partition ratio of the inactivation was approximately 227. 3. Two reactive intermediates, including furanoepoxide and γ-ketoenal, might be responsible for the observed enzyme inactivation. The formation of the intermediates was verified by chemical synthesis. Multiple P450 enzymes, including CYPs 1A2, 2B6, 2C9, 2C19, 2D6, 3A4, and 3A5, were found to be involved in the metabolic activation of LDR. In conclusion, LDR was characterized as a mechanism-based inactivator of CYP2C9.

Entities:  

Keywords:  CYP2C9; drug–drug interactions; linderane; mechanism-based inactivation; reactive metabolite

Mesh:

Substances:

Year:  2015        PMID: 26068520     DOI: 10.3109/00498254.2015.1041002

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product.

Authors:  Ole Kristian Forstrønen Thu; Olav Spigset; Bent Hellum
Journal:  Pharmacol Res Perspect       Date:  2017-08

2.  Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions.

Authors:  Tingting Zhang; Ting Peng; Jinqiu Rao; Kai Wang; Feng Qiu
Journal:  J Anal Methods Chem       Date:  2022-03-10       Impact factor: 2.193

3.  Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3.

Authors:  Wei Xie; Yangliang Ye; Ying Feng; Tifei Xu; Suling Huang; Jianhua Shen; Ying Leng
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.